POLE and melanoma: Here, our aim was to investigate whether patients in the Hungarian melanoma cohort (n = 17) with increased risk carry any pathogenic or likely pathogenic germline variants of the BRCA2, POLE, WRN, FANCI, PALB2, and RAD54B genes associated with melanoma survival and response to therapy.